newsfilter
← Latest News
GlobeNewswire·

Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2025 Financial Results

  • Aligos Therapeutics reported business progress & financial results for the fourth quarter & full year 2025 on March 05, 2026.
  • The Phase 2 B-SUPREME study of pevifoscorvir sodium completed enrollment of 60 HBeAg- participants in January 2026.
  • Enrollment of HBeAg+ participants continues in the B-SUPREME study with top-line data expected in 2027.
  • ALG-170675, a dual-mechanism antisense oligonucleotide developed with Amoytop, advanced into IND-enabling studies.
  • In vivo data for ALG-055009 showed synergistic weight loss when combined with semaglutide or tirzepatide, achieving up to 40% body weight loss in mice.
  • James Hassard was appointed Executive Vice President, Chief Commercial Officer to build global commercial capabilities.
  • Cash, cash equivalents, & investments totaled $77.8 million as of December 31, 2025, funding operations into the third quarter of 2026.
  • Net loss for Q4 2025 was $19.9 million, compared to $82.2 million in Q4 2024.
  • Net loss for the full year 2025 was $24.2 million, compared to $131.2 million in 2024.
  • Research & development expenses for the full year 2025 were $69.5 million, slightly down from $70.3 million in 2024.
  • General & administrative expenses for the full year 2025 were $20.7 million, down from $22.8 million in 2024.
  • Change in fair value of common warrants generated $60.2 million income in 2025, contrasting with a $46.1 million loss in 2024.